Not a Single Disease, but a Family of Tumors
Brain tumors fall broadly into two groups: primary tumors arising directly from brain tissue, and metastatic tumors that spread to the brain from elsewhere in the body. The primary group includes the glioma family (astrocytoma, oligodendroglioma, glioblastoma), meningiomas which are mostly benign, pituitary adenomas that may have hormonal effects, acoustic neuroma arising from the balance nerve, and central nervous system lymphoma. Metastatic tumors most often originate from the lung, breast, melanoma and kidney, and frequently appear in more than one focus. How treatment is shaped is determined together by pathology (tissue diagnosis), genetic markers such as IDH, MGMT and 1p/19q, and the patient’s overall clinical condition. So the statement “I have a brain tumor” does not, by itself, tell us how it should be treated.
The Concept of “Maximal Safe Resection”
If contemporary tumor surgery had to be summed up in one sentence, it would be: remove the tumor while preserving healthy functional tissue. Particularly in gliomas, the volume of tumor removed affects both survival and time to recurrence, while preserved function directly determines the patient’s quality of life after surgery. Too aggressive an approach can cause paralysis or loss of speech; too cautious an approach sets the stage for early recurrence. Tools that help strike this delicate balance include the high-magnification operating microscope, neuro-navigation that turns MRI/CT data into a real-time road map, functional MRI and DTI tractography that show motor and language pathways in advance, awake craniotomy when needed, and the 5-ALA fluorescence technique that makes glioma tissue visible under light. However, not all of these technologies are required in every case; the location of the lesion and surgical experience determine which ones come into play.
When Is Surgery the Answer, and When Another Path?
Typical situations where surgery is the first choice include a symptomatic or rapidly growing meningioma, a glioma in a position suitable for removal, a pituitary adenoma that threatens vision or secretes hormones (via the endoscopic transsphenoidal route), a single brain metastasis with the primary disease under control, and embryonal tumors of childhood. By contrast, in some situations the scalpel is not the answer on its own: in central nervous system lymphoma the treatment is not resection but chemotherapy and radiotherapy after biopsy; in deep locations such as the brainstem or thalamus, biopsy and Gamma Knife often come to the fore; for multiple metastases, Gamma Knife or whole-brain radiotherapy is preferred; and for a small, silent meningioma or a small acoustic neuroma, monitoring or radiosurgery may be on the agenda. This decision is never made by a single physician; it is the product of a joint assessment by the neurosurgeon, neuroradiologist, radiation oncologist and medical oncologist.
The Surgical Journey and Afterwards
The process begins with a detailed neurological examination, contrast-enhanced MRI, functional MRI and tractography where needed, a team meeting and an anesthesia assessment. During surgery the patient is positioned according to the location of the tumor; while most cases are performed under general anesthesia, an awake technique is used when needed for tumors adjacent to speech or movement areas. Today a narrow strip shaved along the incision is usually enough; shaving the entire head is now an exceptional practice. The bone flap is lifted, the dura is opened, the tumor is removed under the microscope with navigation, and the layers are repaired one by one. Depending on the type of tumor, the operation may take between 2 and 8 hours. This is usually followed by 24–48 hours of intensive-care monitoring and a total hospital stay of 3–7 days; a follow-up MRI assesses how much tumor was removed, and radiotherapy or chemotherapy is planned if the pathology result requires it.
Speaking About Risks Without Hiding Them
Brain tumor surgery is a major operation and its risks must be shared openly: bleeding, infection, temporary or permanent neurological loss depending on the tumor’s location, brain swelling that can last several days after surgery, and the possibility of seizures are among the foremost. These rates fluctuate according to the tumor’s location and size, the patient’s age and accompanying illnesses; an experienced team and meticulous planning markedly reduce these risks. Outcomes also vary considerably with the tumor type: with a benign meningioma, long-term control is often possible; in a low-grade glioma, control can be achieved but the chance of recurrence remains; in high-grade tumors such as glioblastoma the main goal is to extend time while preserving quality of life. We do not promise definite results or guarantees; expectations are placed honestly on the table before surgery.